Insulet (NASDAQ:PODD) Price Target Raised to $390.00

by · The Cerbat Gem

Insulet (NASDAQ:PODD – Free Report) had its price objective lifted by Truist Financial from $365.00 to $390.00 in a research report released on Friday morning, MarketBeat reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

A number of other equities research analysts have also recently issued reports on PODD. JPMorgan Chase & Co. raised their target price on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Stifel Nicolaus started coverage on shares of Insulet in a research note on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price for the company. Royal Bank Of Canada upped their target price on shares of Insulet from $350.00 to $365.00 and gave the stock an “outperform” rating in a research report on Friday, October 10th. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average price target of $371.38.

Check Out Our Latest Analysis on PODD

Insulet Stock Performance

NASDAQ PODD traded up $0.53 during trading hours on Friday, reaching $320.35. The company’s stock had a trading volume of 544,810 shares, compared to its average volume of 719,407. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The business has a 50-day simple moving average of $325.06 and a 200 day simple moving average of $310.30. Insulet has a 52 week low of $230.05 and a 52 week high of $353.50. The stock has a market cap of $22.55 billion, a PE ratio of 97.37, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts predict that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PODD. Larson Financial Group LLC lifted its position in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet in the first quarter valued at $26,000. SouthState Corp boosted its position in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the period. True Wealth Design LLC boosted its position in shares of Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the period. Finally, Kozak & Associates Inc. purchased a new position in shares of Insulet during the second quarter valued at $32,000.

Insulet Company Profile

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

See Also